CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Key Points Company and Industry Overview 1. Company Name and Stock Symbol: CRISPR Therapeutics AG (NASDAQ: CRSP) [2] 2. Industry: Biotechnology, specifically gene editing and gene therapy [3] 3. Business Segments: Hemoglobinopathies (heme), oncology, autoimmune, cardiovascular medicines, and rare diseases [3] Pipeline and Products 4. Clinical Programs: Five programs in various disease areas, including oncology, autoimmune, cardiovascular, and rare diseases [3] 5. Preclinical Programs: Ten preclinical programs with promising potential [3] 6. Approved Drug: CASGEVY, a hemoglobinopathy treatment, partnered with Vertex [4] Financial and Business Performance 7. Revenue: Not specified in the provided text [3] 8. Business Model: Divided into four franchises, with hemoglobinopathies being the core [3] Future Outlook 9. Outlook: One of the most consequential years in the company's journey [5] 10. Risk Factors: Encourages participants to visit the company's website for a full risk list [6] Additional Information 11. Conference: 43rd Annual JPMorgan Healthcare Conference [2] 12. Date: January 14, 2025 [2] 13. Time: 5:15 PM ET [2] 14. Participants: Samartha Kulkarni (CEO and Chairman), Fanchen Zhou (JPMorgan) [2]